Advaxis’ (NASDAQ:ADXS) ADSX-NEO has demonstrated significant anti-tumor activity in a Phase 1 study of patients with certain types of advanced or metastatic solid tumors.
ADXS-NEO is a live, attenuated Listeria monocytogenes immunotherapy. It is designed to generate an immune response against some 40 tumor-specific neoantigens detected in a patient’s own tumor.
Preliminary results of the Phase 1 trial demonstrated significant anti-tumor immunity – including T cell responses to neoantigens and antigen spreading – within one week of the first dose.
“The patients being evaluated for safety and tolerability in Part A all have late-stage disease and have been treated with numerous prior therapies. As a result, we did not expect to observe significant clinical activity in this cohort,” Andres Gutierrez, CMO of Advaxis, said in a statement.
The ongoing trial will evaluate the safety, tolerability and preliminary clinical immunological activity of ADXS-NEO alone and in combination with anti-PD-1 antibody therapy.
